Back to today’s briefing

Story perspectives

ctDNA Monitoring Boosts Survival for Stage III Melanoma Patients

4/29/2025

23 2

Summary

Story summary

A groundbreaking phase III trial revealed that monitoring circulating tumor DNA (ctDNA) can be a game-changer for stage III melanoma patients after surgery. The findings indicate that detecting ctDNA is linked to better recurrence-free and overall survival rates, paving the way for personalized treatments for those with BRAF V600-positive melanoma.

1 of 1

Story summary

A groundbreaking phase III trial revealed that monitoring circulating tumor DNA (ctDNA) can be a game-changer for stage III melanoma patients after surgery. The findings indicate that detecting ctDNA is linked to better recurrence-free and overall survival rates, paving the way for personalized treatments for those with BRAF V600-positive melanoma.